Eyetech To Become Full OSI Subsidiary Under $935 Mil. Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
OSI's acquisition of Macugen developer Eyetech will pit the company against its Tarceva partner Genentech in the macular degeneration market.
You may also be interested in...
OSI Is Reconsidering Acquisition Of Eyetech Following Genentech's Lucentis Results
OSI says it needs time to "assess the possible impact" of recent data from Eyetech rival Genentech's macular degeneration therapy.
OSI Is Reconsidering Acquisition Of Eyetech Following Genentech's Lucentis Results
OSI says it needs time to "assess the possible impact" of recent data from Eyetech rival Genentech's macular degeneration therapy.
Genentech/OSI's Tarceva Given Sept. 13 Cmte. Review For Pancreatic Cancer
Supplemental NDA is based on a single Phase III trial of Tarceva plus Lilly's Gemzar vs. Gemzar and placebo.